{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T13:58:25.238844+00:00","company":{"ticker":"CURX","cik":2025942,"company_name":"Curanex Pharmaceuticals Inc"},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"exchange_compliance_notice","fact_key":"54192e7d53ccc770b60ff230440e7bac8a254c0a","cik":2025942,"ticker":"CURX","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2025-11-06T23:59:59+00:00","payload":{"company_response":"none","compliance_status":"deficient","cure_deadline":"2026-05-04","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-11-05","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Curanex Pharmaceuticals Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 5, 2025, Curanex Pharmaceuticals Inc,\na Nevada corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s\ncommon stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid\nprice (the “Minimum Bid Price”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule\n5550(a)(2) (the “Notice”). This Notice has no immediate","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-021028","anchor_url":"https://secwatch.observer/filing/0001493152-25-021028#claim-54192e7d53ccc770b60ff230440e7bac8a254c0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2025942/000149315225021028/0001493152-25-021028-index.htm"},{"fact_type":"equity_issuance","fact_key":"4ad6b7bae4b9b810ed014675c09ca0402c238471","cik":2025942,"ticker":"CURX","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2025-09-29T23:59:59+00:00","payload":{"action":"pipe","consideration_text":"$200,000","effective_date":"2025-09-25","item_codes_triggered":["3.02"],"purchaser":"Xiaohong Song","security_type":"common_stock","shares_text":"28,312 shares"},"claim":"Curanex Pharmaceuticals Inc issued 28,312 shares of common stock to Xiaohong Song for $200,000.","evidence_excerpt":"On September 25, 2025, Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”), issued 28,312 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to Xiaohong Song, an investor that entered into Amended and Restated Subscription Agreement with the Company on November 27, 2024 (the “Agreement”). In accordance with the terms of the Agreement, in consideration of $200,000 subscribed for by Mr. Song, the Shares were issued following successful closing of the Company’s initial public offering (the “IPO”) on August 27, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-015986","anchor_url":"https://secwatch.observer/filing/0001493152-25-015986#claim-4ad6b7bae4b9b810ed014675c09ca0402c238471","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2025942/000149315225015986/0001493152-25-015986-index.htm"}]}